In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PTC Therapeutics sells $250mm in convertible debt financing

Executive Summary

Rare disease-focused PTC Therapeutics Inc. sold $250mm aggregate principal amount of its 1.5% convertible senior notes due 2026 to qualified institutional buyers. The notes convert at an initial rate of 19.0404 shares of common stock per $1k principal amount, or $52.52 per share (its stock is currently averaging $43.07).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies